Quince Therapeutics Reports CEO and COO Conditional Resignations

What Happened
Quince Therapeutics (QNCX) filed an 8‑K on July 31, 2026 announcing that Dirk Thye (CEO and CMO, and board member) and Brendan Hannah (COO, CBO and Chief Compliance Officer) tendered conditional resignations effective two business days after the Company’s Special Meeting of Stockholders (anticipated Sept. 25, 2026), contingent on stockholder approval of three proposals related to the Company’s recent acquisition and PIPE financing. The resignations and successor appointments are tied to approval of (1) a conversion-related issuance that would exceed 20% of outstanding common shares under Nasdaq Rule 5635(a), (2) a minimum-price issuance matter under Nasdaq Rule 5635(d), and (3) an amendment to increase authorized common shares from 250,000,000 to 275,000,000.

Key Details

• Resignations effective at the “Effective Time”: two business days after the Special Meeting (Special Meeting anticipated Sept. 25, 2026) and contingent on stockholder approval of three proposals.
• Conditional successors approved by the Board to take effect at the Effective Time: Brigette Roberts, M.D. as CEO; John Militello, CPA as CFO; Keith R. Fandrick, Ph.D. as COO. All three served in leadership roles at Orphai prior to the acquisition.
• The Conversion Proposal would result in issuance of shares (from Series C Preferred conversion, PIPE warrants and assumed Orphai option conversions) that will represent more than 20% of outstanding common stock (Nasdaq Listing Rule 5635(a)).
• Board will reduce size from five directors to four immediately upon Dr. Thye’s resignation and intends to add an independent director; Thye and Hannah remain eligible for previously disclosed retention bonuses (Form 8‑K filed May 18, 2026) and any severance under existing agreements.

Why It Matters

• Governance and leadership transition: a potential CEO/C-suite change is material for strategy and execution—successors are internal leaders from the acquired Orphai business, signaling continuity in integration.
• Shareholder approval triggers both management changes and significant equity actions: the Conversion Proposal involves dilution (issuance >20%), and the company is seeking to increase authorized shares, both directly relevant to current and prospective investors.
• Financial implications: approval may result in meaningful dilution to existing shareholders and could affect voting power and share structure; retention and severance payments may also affect near‑term cash outflows.

Keywords: CEO, CFO, COO, resignation, succession, acquisition, Orphai, PIPE, Series C, conversion, dilution, Nasdaq Rule 5635, authorized shares, stockholder vote.